Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 31

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 31
---
 solicitation or need help submitting a proxy or voting your shares of Enfusion Common Stock 
 or Enfusion Class B Common Stock, you should contact Enfusion or Innisfree:                                                                                                                                                                             |

| Enfusion, Inc.                                                 
 125 South Clark Street, Suite 750                              
 Chicago, IL 60603 (312) 253-9800 Attention: Investor Relations |     | Innisfree M&A Incorporated                                                       
 501 Madison Avenue, 20th Floor                                                   
 New York City, NY 10022 Banks and                                                
 Brokerage Firms Call: (212) 750-5833 Stockholders Call Toll Free: (877) 750-0637 |

12

SUMMARY

The following summary highlights selected information described in more detail elsewhere in this Proxy Statement/Prospectus and the documents incorporated by reference into this Proxy Statement/Prospectus and may not contain all the information that may be important to you. To understand the Transactions and the matters being voted on by Enfusion Stockholders at the Special Meeting more fully, and to obtain a more complete description of the terms of the Merger Agreement, you should carefully read this entire document, including the annexes, and the documents to which Clearwater and Enfusion refer you. Each item in this summary includes a page reference directing you to a more complete description of that topic. See the section titled “Where You Can Find More Information.”

The Parties(see pages 43 and 44)

Enfusion

Enfusion was formed as a
Delaware corporation on June 11, 2021 under the name Enfusion, Inc. Enfusion provides SaaS solutions for portfolio management, order and execution management, accounting and analytics. Enfusion’s clients include large global hedge fund
managers, institutional asset managers, family offices, and other institutional investors. Enfusion is headquartered in Chicago, Illinois, and has offices in New York City, London, Dublin, Hong Kong, Singapore, Mumbai, Bengaluru and Sydney.

Enfusion Common Stock is listed on the NYSE under the ticker symbol “ENFN.” Enfusion has its executive offices located at 125 South
Clark Street, Suite 750, Chicago, Illinois 60603, and can be reached by phone at (312) 253-9800.

Enfusion OpCo

Enfusion OpCo was formed as a Delaware limited liability company on August 23, 1995, under the name Enfusion Ltd. LLC. All of
Enfusion’s business has been conducted through Enfusion OpCo